Roche shows Tecen­triq/Avastin com­bo helps liv­er can­cer pa­tients live longer

With an eye on a swelling Chi­nese mar­ket, Roche un­veiled Phase III da­ta show­ing a com­bi­na­tion of Tecen­triq, its im­munother­a­py, and Avastin could help pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER